BRIEF-Biocryst Announces FDA Acceptance Of NDA For Orladeyo (Berotralstat) Oral Granules In Patients With Hereditary Angioedema Aged 2 To 11 Years

Reuters

14 May

BRIEF-Biocryst Announces FDA Acceptance Of NDA For Orladeyo (Berotralstat) Oral Granules In Patients With Hereditary Angioedema Aged 2 To 11 Years

May 14 (Reuters) - BioCryst Pharmaceuticals Inc BCRX.O:

BIOCRYST ANNOUNCES FDA ACCEPTANCE OF NDA FOR ORLADEYO® (BEROTRALSTAT) ORAL GRANULES IN PATIENTS WITH HEREDITARY ANGIOEDEMA AGED 2 TO 11 YEARS
BIOCRYST PHARMACEUTICALS INC: FDA GRANTS PRIORITY REVIEW OF APPLICATION, WITH PDUFA TARGET ACTION DATE OF SEPTEMBER 12, 2025
BIOCRYST PHARMACEUTICALS: FILED LINE EXTENSION APPLICATION FOR USE OF ORLADEYO ORAL GRANULES IN PATIENTS WITH HAE AGED 2-11 YEARS WITH EMA

Source text: ID:nGNXb5BYG9

Further company coverage: BCRX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2535025551"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535025551\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2535025551?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-14 19:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535025551","market":"us","top_or_hot":-1,"title":"BRIEF-Biocryst Announces FDA Acceptance Of NDA For Orladeyo (Berotralstat) Oral Granules In Patients With Hereditary Angioedema Aged 2 To 11 Years","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Biocryst Announces FDA Acceptance Of NDA For Orladeyo (Berotralstat) Oral Granules In Patients With Hereditary Angioedema Aged 2 To 11 Years</title></head><body><p><span>May 14 (Reuters)</span><span> - </span>BioCryst Pharmaceuticals Inc <span>BCRX.O</span>:</p><ul><li><p>BIOCRYST ANNOUNCES FDA ACCEPTANCE OF NDA FOR ORLADEYO® (BEROTRALSTAT) ORAL GRANULES IN PATIENTS WITH HEREDITARY ANGIOEDEMA AGED 2 TO 11 YEARS</p></li><li><p>BIOCRYST PHARMACEUTICALS INC: FDA GRANTS PRIORITY REVIEW OF APPLICATION, WITH PDUFA TARGET ACTION DATE OF SEPTEMBER 12, 2025</p></li><li><p>BIOCRYST PHARMACEUTICALS: FILED LINE EXTENSION APPLICATION FOR USE OF ORLADEYO ORAL GRANULES IN PATIENTS WITH HAE AGED 2-11 YEARS WITH EMA</p></li></ul><p>Source text: <span>ID:nGNXb5BYG9</span></p><p>Further company coverage: <span>BCRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Biocryst Announces FDA Acceptance Of NDA For Orladeyo (Berotralstat) Oral Granules In Patients With Hereditary Angioedema Aged 2 To 11 Years</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Biocryst Announces FDA Acceptance Of NDA For Orladeyo (Berotralstat) Oral Granules In Patients With Hereditary Angioedema Aged 2 To 11 Years\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-14 19:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Biocryst Announces FDA Acceptance Of NDA For Orladeyo (Berotralstat) Oral Granules In Patients With Hereditary Angioedema Aged 2 To 11 Years</title></head><body><p><span>May 14 (Reuters)</span><span> - </span>BioCryst Pharmaceuticals Inc <span>BCRX.O</span>:</p><ul><li><p>BIOCRYST ANNOUNCES FDA ACCEPTANCE OF NDA FOR ORLADEYO® (BEROTRALSTAT) ORAL GRANULES IN PATIENTS WITH HEREDITARY ANGIOEDEMA AGED 2 TO 11 YEARS</p></li><li><p>BIOCRYST PHARMACEUTICALS INC: FDA GRANTS PRIORITY REVIEW OF APPLICATION, WITH PDUFA TARGET ACTION DATE OF SEPTEMBER 12, 2025</p></li><li><p>BIOCRYST PHARMACEUTICALS: FILED LINE EXTENSION APPLICATION FOR USE OF ORLADEYO ORAL GRANULES IN PATIENTS WITH HAE AGED 2-11 YEARS WITH EMA</p></li></ul><p>Source text: <span>ID:nGNXb5BYG9</span></p><p>Further company coverage: <span>BCRX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCRX","symbol_name":"BioCryst制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250514:nTUAC8HS9H:1","article_id":"2535025551","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535025551","pubTimestamp":1747223758,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Biocryst Announces FDA Acceptance Of NDA For Orladeyo (Berotralstat) Oral Granules In Patients With Hereditary Angioedema Aged 2 To 11 YearsMay 14 (Reuters) - BioCryst Pharmaceuticals Inc BCRX.O","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BCRX":"BioCryst制药","BK4139":"生物科技","BK4547":"WSB热门概念"},"translate_title":"BRIEF-Biocryst宣布FDA接受Orladeyo（Berotralstat）口服颗粒治疗2至11岁遗传性血管性水肿患者的NDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCRX":0.9},"content_text":"BRIEF-Biocryst Announces FDA Acceptance Of NDA For Orladeyo (Berotralstat) Oral Granules In Patients With Hereditary Angioedema Aged 2 To 11 YearsMay 14 (Reuters) - BioCryst Pharmaceuticals Inc BCRX.O:BIOCRYST ANNOUNCES FDA ACCEPTANCE OF NDA FOR ORLADEYO® (BEROTRALSTAT) ORAL GRANULES IN PATIENTS WITH HEREDITARY ANGIOEDEMA AGED 2 TO 11 YEARSBIOCRYST PHARMACEUTICALS INC: FDA GRANTS PRIORITY REVIEW OF APPLICATION, WITH PDUFA TARGET ACTION DATE OF SEPTEMBER 12, 2025BIOCRYST PHARMACEUTICALS: FILED LINE EXTENSION APPLICATION FOR USE OF ORLADEYO ORAL GRANULES IN PATIENTS WITH HAE AGED 2-11 YEARS WITH EMASource text: ID:nGNXb5BYG9Further company coverage: BCRX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}